Are urgent care clinics the salve the medical industry needs?

By Ben Levine for Kapitall.

If you’re an American, you likely know someone or have at least heard of someone who has been to the hospital for something fairly trivial, sat for hours awaiting treatment, and was handed an exorbitant bill.  

Stories like this are abound. Much of the issue seems to be that patients are being billed for hospital stays that may not have been necessary, and those providing healthcare in various capacities are catching on. 

As an alternative to the traditional go-to-the-emergency-room model, urgent care clinics are cropping up, offering short waits, short treatment times, and low costs. Essentially, they’re flipping the hospital model of long, high-margin treatments, instead profiting with low margins, high traffic and fast patient turnaround. 

Pharmacy operators like Walgreen ( WAG), CVS/Caremark ( CVS) and Wal-Mart ( WMT) have opened in-store clinics for convenient treatment at a wider range of hours than going to the doctor’s office, but you probably won’t get to see an actual doctor. Others, on the other hand, are opening urgent care centers, a similar concept wherein patients see an actual doctor. There are now over 10,000 of them across the country, and they’re building some brand recognition. In 2010 healthcare giant Humana ( HUM) purchased Concentra, the largest urgent care provider at over 300 locations. Health insurer WellPoint ( WLP) has followed suit in opening urgent care centers. Other than Concentra, the largest urgent care chains are U.S HealthWorks, MedExpress, afc, and NextCare

What’s more, even for-profit hospital chains are getting in on the action. As of May, the Tenet Healthcare Corporation ( THC) had opened 23 urgent care centers nationwide.

Is urgent care the way of the future for non-critical healthcare? Take a look at the list below and let us know what you think in the comments.

Click on the interactive chart to view data over time. 

 

1. CVS Caremark Corporation ( CVS): Operates as a pharmacy services company in the United States. Market cap at $84.93B, most recent closing price at $71.37.

 

 

2. Humana Inc. ( HUM): Humana Inc. offers various health and supplemental benefit plans in the United States. Market cap at $17.73B, most recent closing price at $113.69.

 

 

3. Tenet Healthcare Corp. ( THC): Operates acute care hospitals and related health care facilities. Market cap at $4.88B, most recent closing price at $48.33.

 

 

4. Walgreen Co. ( WAG): Engages in the operation of a chain of drugstores in the United States. Market cap at $63.15B, most recent closing price at $66.52.

 

 

5. WellPoint Inc. ( WLP): Operates as a health benefits company in the United States. Market cap at $27.5B, most recent closing price at $90.93.

 

 

6. Wal-Mart Stores Inc. ( WMT): Operates retail stores in various formats worldwide. Market cap at $237.65B, most recent closing price at $73.35.

 

 

(List compiled by Ben Levine. Analyst ratings sourced from Zacks Investment Research, all other data sourced from Finviz.)

 

Kapitall Wire is a division of New Kapitall Holdings, LLC. Kapitall Generation, LLC is a wholly owned subsidiary of New Kapitall Holdings, LLC. Kapitall Wire offers free investing ideas, intended for educational information purposes only. It should not be construed as an offer to buy or sell securities, or any other product or service provided by New Kapitall Holdings, LLC, and its affiliate companies.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says